ATE493144T1 - Zusammensetzung und verfahren zur abtötung von tumoren - Google Patents
Zusammensetzung und verfahren zur abtötung von tumorenInfo
- Publication number
- ATE493144T1 ATE493144T1 AT03745189T AT03745189T ATE493144T1 AT E493144 T1 ATE493144 T1 AT E493144T1 AT 03745189 T AT03745189 T AT 03745189T AT 03745189 T AT03745189 T AT 03745189T AT E493144 T1 ATE493144 T1 AT E493144T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- prodrug
- promoter
- subject
- killing tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001443586 Atadenovirus Species 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10141—Use of virus, viral particle or viral elements as a vector
- C12N2710/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS1456A AUPS145602A0 (en) | 2002-03-28 | 2002-03-28 | Composition and method for killing tumours |
| PCT/AU2003/000381 WO2003082323A1 (en) | 2002-03-28 | 2003-03-28 | A composition and method for killing of tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493144T1 true ATE493144T1 (de) | 2011-01-15 |
Family
ID=3835044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03745189T ATE493144T1 (de) | 2002-03-28 | 2003-03-28 | Zusammensetzung und verfahren zur abtötung von tumoren |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060177423A1 (de) |
| EP (1) | EP1494705B1 (de) |
| JP (1) | JP4508656B2 (de) |
| AT (1) | ATE493144T1 (de) |
| AU (2) | AUPS145602A0 (de) |
| CA (1) | CA2519642A1 (de) |
| DE (1) | DE60335535D1 (de) |
| WO (1) | WO2003082323A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771679B2 (en) | 2008-08-13 | 2014-07-08 | The John Hopkins University | Prodrug activation in cancer cells using molecular switches |
| WO2012008860A2 (en) | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
| US10080784B2 (en) | 2011-02-18 | 2018-09-25 | Southern Research Institute | Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583198A (en) * | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
| AUPM710194A0 (en) * | 1994-07-26 | 1994-08-18 | Commonwealth Scientific And Industrial Research Organisation | Virus vector |
| US7037712B2 (en) * | 1994-07-26 | 2006-05-02 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
| AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
| US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| DE69739181D1 (de) * | 1996-08-12 | 2009-02-05 | Celgene Corp | Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel |
| US5772993A (en) * | 1997-01-21 | 1998-06-30 | The University Of Virginia Patent Foundation | Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues |
| WO2000052156A1 (en) * | 1999-03-01 | 2000-09-08 | Commonwealth Scientific And Industrial Research Organisation | Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene |
| CA2469623C (en) * | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
-
2002
- 2002-03-28 AU AUPS1456A patent/AUPS145602A0/en not_active Abandoned
-
2003
- 2003-03-28 AT AT03745189T patent/ATE493144T1/de not_active IP Right Cessation
- 2003-03-28 US US10/509,513 patent/US20060177423A1/en not_active Abandoned
- 2003-03-28 AU AU2003215419A patent/AU2003215419B2/en not_active Ceased
- 2003-03-28 JP JP2003579860A patent/JP4508656B2/ja not_active Expired - Fee Related
- 2003-03-28 EP EP03745189A patent/EP1494705B1/de not_active Expired - Lifetime
- 2003-03-28 CA CA002519642A patent/CA2519642A1/en not_active Abandoned
- 2003-03-28 DE DE60335535T patent/DE60335535D1/de not_active Expired - Lifetime
- 2003-03-28 WO PCT/AU2003/000381 patent/WO2003082323A1/en not_active Ceased
-
2008
- 2008-11-20 US US12/292,499 patent/US20090104154A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AUPS145602A0 (en) | 2002-05-09 |
| AU2003215419B2 (en) | 2008-10-30 |
| JP4508656B2 (ja) | 2010-07-21 |
| US20090104154A1 (en) | 2009-04-23 |
| CA2519642A1 (en) | 2003-10-09 |
| US20060177423A1 (en) | 2006-08-10 |
| EP1494705B1 (de) | 2010-12-29 |
| WO2003082323A1 (en) | 2003-10-09 |
| JP2005531525A (ja) | 2005-10-20 |
| AU2003215419A1 (en) | 2003-10-13 |
| DE60335535D1 (de) | 2011-02-10 |
| EP1494705A1 (de) | 2005-01-12 |
| EP1494705A4 (de) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20041071A2 (en) | Methods of treating hepatitis | |
| TW200738270A (en) | Method of treating depression using a TNFα antibody | |
| UA85041C2 (ru) | Способ лечения кишечной непроходимости | |
| MY169308A (en) | Treatment of tnf? related disorders | |
| NO20045354L (no) | Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser | |
| UA86570C2 (ru) | Способ лечения некротизирующего энтероколита | |
| ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
| EP1481077A4 (de) | Mitotische kinesin-hemmer | |
| PL374190A1 (en) | Mitotic kinesin inhibitors | |
| TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
| ATE424388T1 (de) | Mitotische kinesinhemmer | |
| MX2008012748A (es) | Un proceso para la concentracion de un polipeptido. | |
| BRPI0410331A (pt) | método para tratar doença de disco degenerativa | |
| WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
| ATE419340T1 (de) | Neue carbonylreduktase, deren gen sowie verfahren zur verwendung davon | |
| ATE514718T1 (de) | Peptabody für krebsbehandlung | |
| DE60335535D1 (de) | Zusammensetzung und verfahren zur abtötung von tumoren | |
| WO2024036204A3 (en) | Modified antibodies and methods of use thereof | |
| EP1602669A4 (de) | Antikörper gegen tumorspezifisches antigen als target | |
| ATE475408T1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
| ZA202304030B (en) | Modified cxcl10 for immunotherapy of cancer diseases | |
| WO2021231549A3 (en) | Engineered gene-editing proteins | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| ATE451457T1 (de) | Verfahren zur dipeptidherstellung | |
| WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |